Hanmi Pharm
Update in progress128940.KS (KSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Hanmi Pharm. Co., Ltd. is a South Korea-based biopharmaceutical company focused on developing and selling medicines worldwide, including Korea, China, Japan, and the United States. It targets areas with high unmet medical needs such as obesity, metabolism, oncology, and rare diseases. Its product Gugutams combines tamsulosin and tadalafil for obstructive prostatic growth and erectile dysfunction. Hanmi collaborates with MEDIC Life Sciences to identify cancer biomarkers. Founded in 1973.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- -0.23
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketKSE (KSC)
- LocationSouth Korea
- CEOMr. Jae-Hyun Park
- Founded1973
- Websitewww.hanmipharm.com